Drug intelligence / Profile preview

WOL071-007

Development stage: Phase 1
Lead developer: Dr August Wolff
Modality: Small Molecules
Administration: Topical

Overview

WOL071-007 is a synthetic small molecule drug developed as a kappa opioid receptor agonist. It has been investigated primarily for its potential to inhibit inflammation and pruritus (itch) in atopic dermatitis, with preclinical models demonstrating efficacy in reducing these symptoms. The drug acts by activating the kappa opioid receptor, which is known to modulate itch and inflammatory pathways in the skin. Clinical studies have focused on evaluating its safety, tolerability, pharmacokinetics, and efficacy when applied topically to lesional or non-lesional skin of patients with atopic dermatitis[1][2][3].

Targets

KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on WOL071-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WOL071-007.

Explore the full profile